Christopher J Hammett
Overview
Explore the profile of Christopher J Hammett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Montalescot G, van t Hof A, Bolognese L, Cantor W, Cequier A, Chettibi M, et al.
JACC Cardiovasc Interv
. 2016 Mar;
9(7):646-56.
PMID: 26952907
Objectives: The aim of this landmark exploratory analysis, ATLANTIC-H(24), was to evaluate the effects of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention (PCI) in the...
12.
Greenslade J, Parsonage W, Than M, Scott A, Aldous S, Pickering J, et al.
Ann Emerg Med
. 2015 Sep;
67(4):478-489.e2.
PMID: 26363570
Study Objective: We derive a clinical decision rule for ongoing investigation of patients who present to the emergency department (ED) with chest pain. The rule identifies patients who are at...
13.
Briffa T, Hammett C, Cross D, MacIsaac A, Rankin J, Board N, et al.
Aust Health Rev
. 2015 Apr;
39(4):379-386.
PMID: 25913297
Objective: The aim of the present study was to explore the association of health insurance status on the provision of guideline-advocated acute coronary syndrome (ACS) care in Australia. Methods: Consecutive...
14.
Montalescot G, van t Hof A, Lapostolle F, Silvain J, Lassen J, Bolognese L, et al.
N Engl J Med
. 2014 Sep;
371(11):1016-27.
PMID: 25175921
Background: The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI)....
15.
Parsonage W, Greenslade J, Hammett C, Lamanna A, Tate J, Ungerer J, et al.
Med J Aust
. 2014 Feb;
200(3):161-5.
PMID: 24528432
Objectives: To validate an accelerated biomarker strategy using a high-sensitivity cardiac troponin T (hs-cTnT) assay for diagnosing acute myocardial infarction (AMI) in patients presenting to the emergency department with chest...
16.
Cullen L, Greenslade J, Than M, Tate J, Ungerer J, Pretorius C, et al.
Heart Lung Circ
. 2013 Dec;
23(5):428-34.
PMID: 24321648
Background: Risk stratification processes for patients with possible acute coronary syndrome (ACS) recommend the use of serial sensitive troponin testing over at least 6h. Troponin assays vary in their analytical...
17.
Cullen L, Aldous S, Than M, Greenslade J, Tate J, George P, et al.
Clin Biochem
. 2013 Dec;
47(6):321-6.
PMID: 24316100
Objectives: Concentrations of troponin measured with high sensitivity troponin assays are raised in a number of emergency department (ED) patients; however many are not diagnosed with acute myocardial infarction (AMI)....
18.
The new Vancouver Chest Pain Rule using troponin as the only biomarker: an external validation study
Cullen L, Greenslade J, Than M, Brown A, Hammett C, Lamanna A, et al.
Am J Emerg Med
. 2013 Nov;
32(2):129-34.
PMID: 24238485
Objectives: To externally evaluate the accuracy of the new Vancouver Chest Pain Rule and to assess the diagnostic accuracy using either sensitive or highly sensitive troponin assays. Methods: Prospectively collected...
19.
Parsonage W, Tate J, Greenslade J, Hammett C, Ungerer J, Pretorius C, et al.
Clin Chem Lab Med
. 2013 Aug;
52(2):e25-7.
PMID: 23924523
No abstract available.
20.
Chew D, French J, Briffa T, Hammett C, Ellis C, Ranasinghe I, et al.
Med J Aust
. 2013 Aug;
199(3):185-91.
PMID: 23909541
Objectives: To characterise management of suspected acute coronary syndrome (ACS) in Australia and New Zealand, and to assess the application of recommended therapies according to published guidelines. Design, Setting And...